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ABSTRACT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been
suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL). However, the infusion
of HTLV-I–infected cells from HTLV-I–positive related donors could lead to the development of donor-
derived ATLL under immunosuppressive conditions. Although most ATLL patients lack a suitable HLA-
matched related donor and require an HTLV-I–negative unrelated donor, little information is currently
available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL. To evaluate the
role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by
UBMT through the Japan Marrow Donor Program (JMDP). Overall survival (OS), progression-free survival,
and cumulative incidence of disease progression and progression-free mortality at 1 year after UBMT were
49.5%, 49.2%, 18.6%, and 32.3%, respectively. Multivariate analysis identified recipient age as an independent
prognostic factor for OS (P  .044). Patients age >50 years who showed nonremission at transplantation
tended to have higher rates of treatment-related mortality. Our observations suggest that UBMT could
represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk
factors.
© 2007 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Adult T-cell leukemia/lymphoma (ATLL) is a pe-
ipheral T-cell neoplasm caused by human T-cell leu-
emia virus type I (HTLV-I) [1,2]. ATLL is generally t
0lassiﬁed into 4 clinical subtypes based on clinical and
aboratory features: acute, chronic, smoldering, and
ymphoma type. Clinically, acute- and lymphoma-
ype ATLL show an aggressive course, with tumor
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Unrelated Bone Marrow Transplantation for Adult T-Cell Leukemia/Lymphoma 91urden, severe hypercalcemia, multiorgan failure, and
oor performance status. ATLL has an extremely
oor prognosis, with a median survival of about 6
onths for the acute type and about 10 months for the
ymphoma type; these patients are usually highly im-
unocompromised and develop various opportunistic
nfections. [3] Furthermore, their tumor cells are usu-
lly resistant to conventional chemotherapies, because
verexpression of multidrug-resistance genes leads to
ntrinsic drug resistance. [4,5] Intensiﬁed chemother-
py [6,7] and autologous stem cell transplantation [8]
ikewise have failed to improve the prognosis. Thus,
lternative treatment strategies for ATLL are needed.
Some cases of successful treatment with allogeneic
tem cell transplantation (allo-HSCT) from an HLA-
atched related donor have been reported, and a
raft-versus-ATLL (GvATLL) effect has been impli-
ated for improving treatments outcomes in trans-
lant patients undergoing transplantation for ATLL.
9–11] However, more than 2/3 of patients with
TLL lack HLA-matched related donors. Further-
ore, approximately 2/3 of the siblings of patients
ith ATLL are HTLV-I carriers [12], and allo-
SCT from an HTLV-I–positive donor may carry a
isk of promoting the development of ATLL through
he addition of a new HTLV-I load on the immuno-
ompromised host. [13,14] Although most ATLL pa-
ients lack a suitable HLA-matched related donor and
equire an unrelated donor to beneﬁt from allo-
SCT, few reports are available concerning the re-
ults of unrelated donor bone marrow transplantation
UBMT) for ATLL [9,11,15–18], and the number of
atients in these few reports has been too small on
hich to base any solid conclusions. Therefore, to
larify the feasibility and efﬁcacy of UBMT from an
TLV-I-negative donor for ATLL, we retrospec-
ively analyzed registered data and clinical outcomes
f UBMT for ATLL through the Japan Marrow Do-
or Program (JMDP).
ATIENTS AND METHODS
atients and Transplantation Procedure
The subjects of this retrospective study consisted
f 33 patients with ATLL (acute type, n  20; lym-
homa type, n 7; not described, n 6) who received
BMT from a donor mediated and recruited through
he JMDP between September 1999 and January
004. The clinical indications for UBMT were deter-
ined by each individual institution. The median time
rom diagnosis of ATLL to UBMT was 8 months
range, 5–28 months). At the time of transplantation,
3 patients were in complete remission (CR), 2 pa-
ients were in partial remission (PR), and 14 patients
ere in nonremission (NR); disease status at the time
f transplantation was not described in 4 patients. CR ctatus was reported in detail for 13 patients, with 11
atients in ﬁrst CR (CR1) and 2 patients in second CR
CR2) (Table 1). All unrelated donors were HTLV-I
ntibody–negative. Serologic typing for HLA-A, -B,
nd -DR was performed using a standard 2-stage com-
lement-dependent test of microcytotoxicity. [19] Al-
eles at the HLA-A, -B, and -DRB1 loci were identi-
ed by high-resolution DNA typing as described
reviously. [20] Serologic typing revealed that 22 pa-
ients were matched at the HLA-A, -B, and -DR loci.
our patients were mismatched at 1 HLA-DR locus,
nd 1 patient was mismatched at 2 loci of HLA-A and
DR. DNA typing revealed that 13 patients were
atched at HLA-A, -B and -DRB1 loci. Ten patients
ere mismatched at 1 locus; 9 patients were mis-
atched at the HLA-DRB1 locus, and the remaining
atient was mismatched at 1 HLA-A locus. Another 4
atients were mismatched at 2 loci. HLA typing data
ere not described in 6 patients. Patient and donor
able 1. Patient characteristics
Characteristic Value
edian age at transplantation, years 49 (range, 24–59)
(range)
ex, n
Male 18
Female 15
erformance status, n
0–1 21
2–4 4
ND 8
ubtypes of ATLL, n
Acute 20
Lymphoma 7
ND 6
isease status at transplantation, n
CR or PR 15
NR 14
ND 4
uration from diagnosis to UBMT, n
Within 1 year 21
Beyond 1 year 11
ND 1
onditioning, n (TBI-containing, 22; non–
TBI-containing, 11)
CST 27
RIST 6
ell dose, n
< 3.0  108/kg 16
> 3.0  108/kg 14
ND 3
VHD prophylaxis, n
CsA  MTX 13
TCR  MTX 20
D indicates not described; CR, complete remission; PR, partial
remission; NR, nonremission; UBMT, unrelated bone marrow
transplantation; TBI, total body irradiation; CST, conventional
stem cell transplantation; RIST, reduced-intensity stem cell
transplantation; GVHD, graft-versus-host disease; CsA, cyclo-
sporine; MTX, methotrexate; TCR, tacrolimus.haracteristics are summarized in Table 2.
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K. Kato et al.92Transplantation was performed according to the
rotocol of each institution; therefore, conditioning
egimens and prophylaxis against graft-versus-host
isease (GVHD) differed among patients. Condition-
ng regimens were myeloablative in 27 patients; total
ody irradiation (TBI) was incorporated in 22 pa-
ients. Reduced-intensity conditioning regimens were
sed in 6 patients. GVHD prophylaxis included cy-
losporine (n 13) and tacrolimus (n 20) combined
ith methotrexate. All recipients received bone mar-
ow transplantation, which was not manipulated.
ssessment of Engraftment, GVHD, Survival, and
rogression-Free Mortality
The day of sustained engraftment was deﬁned as
he ﬁrst of 3 consecutive days with an absolute neu-
rophil count exceeding 0.5  109/L. Acute GVHD
as diagnosed and graded according to the standard
riteria described previously. [21,22] Chronic GVHD
as evaluated according to standard criteria [23] in
atients who survived more than 100 days after trans-
lantation. Overall survival (OS) was deﬁned as the
uration (in days) from transplantation to death from
ny cause. Progression-free survival (PFS) was deﬁned
s days from transplantation to disease progression or
eath from any cause. Progression-free mortality was
eﬁned as death without disease progression.
ata Management and Statistical Considerations
Data were collected by the JMDP using a stan-
ardized report form. Follow-up reports were submit-
ed at 100 days, 1 year, and every subsequent year after
ransplantation. The cumulative incidence of disease
rogression and progression-free mortality were eval-
ated using Gray’s method, [24] considering each
ther risk as a competing risk. OS and PFS were
able 2. Patient and donor characteristics
Characteristic Value
LA-A, -B, and -DRB1 allele mismatches, n
0 13
1 10
2 4
ND 6
ex of donor/patient, n
Male/male 13
Female/female 8
Female/male 5
Male/female 7
xtent of ABO match, n
Match 19
Minor mismatch 4
Major mismatch 7
Major/minor 2
ND 1
D indicates not described.stimated using the Kaplan-Meier method. Potentialonfounding factors considered in the analysis were
ge, sex, disease status, duration from diagnosis to
ransplantation, Eastern Cooperative Oncology
roup (ECOG) performance status, [25] conditioning
egimen, number of bone marrow cells transplanted,
nd presence of grade II–IV acute GVHD. Propor-
ional hazard modeling was used to evaluate any in-
uence of these factors on OS, treating development
f acute GVHD as a time-dependent covariate. Fac-
ors associated with at least borderline signiﬁcance (P
.05) in univariate analyses were subjected to multi-
ariate analyses using backward-stepwise proportional
azards modeling. P values P  .10 were considered
tatistically signiﬁcant.
ESULTS
ngraftment and GVHD
Transplantation outcomes are summarized in Ta-
le 3. The median number of cells transplanted was
.44 108 nucleated cells/kg of recipient body weight
range, 0.58–3.58  108 nucleated cells/kg of recipi-
nt body weight). Five patients (15%) died within 20
ays. Neutrophil engraftment was achieved in 28 pa-
ients. Late graft failure occurred in 1 of these 28
atients, although the patient showed engraftment on
able 3. Transplantation outcome
Value
live/dead, n 19/14
edian follow-up for survivors, days (range) 139 (87–600)
ause of death
Progression, n 2
Death without progression, n 9
Median days after transplantation (range) 32 (10–71)
Late graft failure, n 1
GVHD, n 1
Infection, n 3
TMA, n 2
VOD, n 1
Arrhythmia, n 1
Not described, n 3
isease progression, n 5
Median days after transplantation (range) 122 (61–223)
ngraftment, n
Engraftment 28
Death within 20 days 5
Late graft failure 1
cute GVHD, n
None 3
Grade I 8
Grade II 12
Grade III 3
Grade IV 2
hronic GVHD, n
None 14
Limited 1
Extensive 3
VHD indicates graft-versus-host disease; TMA, thrombotic mi-
croangiopathy; VOD, venooculusive disease.
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Unrelated Bone Marrow Transplantation for Adult T-Cell Leukemia/Lymphoma 93ay 14. Acute GVHD developed in 25 of the 28
atients who achieved engraftment (89%): grade I
VHD in 8 patients, grade II in 12 patients, grade III
n 3 patients, and grade IV in 2 patients. The cumu-
ative incidence of grade II–IV acute GVHD was 61%
Figure 1). Chronic GVHD developed in 4 of 18
atients, with limited disease in 1 patient and extensive
isease in the other 3 patients.
urvival and disease progression
The 1-year OS and PFS were 49.5% (95% conﬁ-
ence interval [CI], 31.2%–78.5%) and 49.2% (95%
I, 33.6%–72.1%), respectively (Figure 2). Disease
rogression was observed in 5 patients, and the me-
ian number of days from transplantation to disease
rogression was 122 (range, 61–223 days). As of the
ast follow-up, 14 deaths had been reported. Primary
ause of death was disease progression in 2 patients
nd was not described in 3 patients, but the other 9
eaths were not due to disease progression (see Table
). Primary causes of transplantation-related death
ithin 100 days after transplantation were late graft
ailure in 1 patient, GVHD in 1 patient, infection in 3
atients (with methicillin-resistant Staphylococcus au-
eus–positive sepsis in 1 patient and pulmonary infec-
ion in 2 patients), thrombotic microangiopathy
TMA) in 2 patients, veno-occlusive disease (VOD) in
patient, and arrhythmia in 1 patient.
nivariate and Multivariate Analyses for OS
Pretransplantation and posttransplant factors were
alculated for OS (Table 4). In univariate analyses, OS
as not signiﬁcantly associated with sex, duration
rom diagnosis to transplantation, ECOG perfor-
ance status, conditioning regimen, number of bone
arrow cells transplanted, or presence of grade II–IV
Figure 1. Cumulative incidence of grade II–IV acutecute GVHD. On the other hand, patient age and cisease status at transplantation were identiﬁed as sig-
iﬁcant independent risk factors. In multivariate anal-
ses, only patient age at transplantation was identiﬁed
s exerting a signiﬁcant independent risk impact on
S (50 years vs 50 years; relative risk, 3.47; 95%
I, 1.03–11.6; P  .044). Disease status at transplan-
ation exerted a marginally signiﬁcant impact on OS
NR vs CR or PR; relative risk, 3.17; 95% CI, 0.96–
0.5; P  .059) (Figure 3).
nfluence of Pretransplantation Factors on Disease
rogression and Progression-Free Mortality
The cumulative incidence of disease progression
nd progression-free mortality at 1 year were 18.6%
nd 32.3%, respectively (Figure 4). To clarify how age
nd disease status at transplantation affected OS, we
valuated the relationship between these factors and
he incidence of progression-free mortality. The cu-
ulative incidence of progression-free mortality was
igniﬁcantly higher in patients age 50 years at trans-
lantation (50% vs 18%; P  .048; Figure 5A). NR at
ransplantation exerted a marginally signiﬁcant effect
n increased progression-free mortality (54% vs 20%;
 .070; Figure 5B).
ISCUSSION
This study analyzed the data and evaluated treat-
ent outcomes for 33 patients with ATLL who re-
eived UBMT. Two important ﬁndings were identi-
ed regarding UBMT for ATLL. First, UBMT from
TLV-I–negative donors for ATLL represents a fea-
ible treatment. Second, recipient age (50 years) and
R disease status at transplantation were independent
isk factors for OS, and patients with ATLL display-
ng these risk factors tended to exhibit higher frequen-
D in patients who achieved neutrophil engraftment.ies of treatment-related mortality.
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K. Kato et al.94igure 2. Probability of progression-free survival (A) and overall survival (B) after unrelated bone marrow transplantation for adult T-cell
eukemia/lymphoma. Dashed lines represent 95% conﬁdence intervals.able 4. Prognosis factors in univariate and multivariate analyses
Univariate Multivariate
Relative risk (95% CI) P Relative risk (95% CI) P
ge >50 versus <50 years 4.03 (1.23–13.3) .022 4.03 (1.23–13.3) .022
ale versus female 0.97 (0.34–2.80) .95
S 0–1 versus 2–4 0.44 (0.11–1.70) .23
R versus CR or PR 3.37 (1.03–11.0) .044 .059
BMT within 1 year versus beyond 1 year 0.54 (0.15–2.00) .35
IST versus CST 0.71 (0.19–2.59) .60
BI versus non-TBI 1.35 (0.45–4.04) .59
ell dose < 3.0  108/kg versus > 3.0  108/kg 0.98 (0.31–3.05) .97
VHD II–IV present versus absent 1.91 (0.50–7.26) .34
I indicates conﬁdence interval; PS, performance status; NR, nonremission; CR, complete remission; PR, partial remission; UBMT, unrelated
bone marrow transplantation; RIST, reduced-intensity stem cell transplantation; CST, conventional stem cell transplantation; TBI, total
body irradiation; GVHD, graft-versus-host disease.
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Unrelated Bone Marrow Transplantation for Adult T-Cell Leukemia/Lymphoma 95ATLL has an extremely poor prognosis, with pro-
ected 2- and 4-year survival rates of 16.7% and 5.0%
or the acute type and 21.3% and 5.7% for the lym-
homa type, respectively. [3] Neither intensiﬁed che-
otherapy nor autologous stem cell transplantation
ave improved the prognosis. Encouraging results for
llo-HSCT for ATLL from HLA-matched related
onors have been reported by several groups; thus,
llo-HSCT may improve the poor prognosis of
TLL. However, the number of patients in most
eports has been too small to allow evaluation of the
fﬁcacy of allo-HSCT for ATLL. The present results
ere derived from a large number of patients who
nderwent transplantation (33 patients) performed
hrough the JMDP. Longer follow-up is, of course,
eeded to conﬁrm the curative potential of allo-
SCT for ATLL. However, the good survival rates
oted here suggest that allo-HSCT is an effective
reatment for ATLL, and that patients with ATLL
Figure 3. Overall survival according to pretransplantaill beneﬁt from allo-HSCT through HTLV-I–neg- mtive unrelated donors, because the OS and PFS rates
t 1 year after UBMT were 49.5% and 49.2%, respec-
ively. Compared with the results for patients with
on-Hodgkin’s lymphoma in the National Marrow
onor Program, the incidence of grade III–IV acute
VHD in the present study was low (18% vs 30%).
26] The outcome in the present study appears to be
avorable, possible due to the lower incidence of grade
II–IV acute GVHD. This observation is compatible
ith previous studies showing a lower incidence of
cute GVHD in Japanese patients compared with
estern patients, which might reﬂect the less diverse
enetic background of in the Japanese population.
27,28]
Frequency of relapse after transplantation differs
etween autologous and allo-HSCT for ATLL. The
se of high-dose chemotherapy with autologous
SCT has been reported in only 9 patients, all of
hom relapsed or died from transplantation-related
tors, age (A) and disease status at transplantation (B).ortality. [8] In contrast, the cumulative incidence of
d
s
a
[
l
o
d
t
(
w
c
i
s
s
a
n
a
t
o
f
t
t
r
p
c
c
w
i
d
a
h
t
d
d
r
t
t
a
s
f
b
h
t
t
a
t
m
f
H
e
o
s
t
n
a
i
r
y
H
n
i
t
[

w
m
r
w
(—) an
K. Kato et al.96isease progression was lower after UBMT in this
tudy. Interestingly, patients with ATLL displaying
cute or chronic GVHD reportedly did not relapse.
9] In another report, patients with ATLL who re-
apsed after allo-HSCT reachieved CR after tapering
r discontinuation of immunosuppressive agents and
onor lymphocyte infusions. [10,11] Reactivation in
ax-speciﬁc CD8-positive cytotoxic T lymphocytes
CTLs), which has been recently shown in patients
ith ATLL after allo-HSCT, may indicate a potential
ontribution of CTLs to anti-ATLL immunity and
nduction of a GvATLL effect. [29] These results
trongly suggest that a GvATLL effect could work on
ome patients with ATLL to prevent relapse after
llo-HSCT. In the present study, neither univariate
or multivariate analysis showed a survival beneﬁt for
cute GVHD. We were unable to analyze the rela-
ionship between chronic GVHD and relapse, because
f the low number of patients with chronic GVHD. In
act, the number of patients may have been insufﬁcient
o conﬁrm GvATLL in this study. On the other hand,
he absence of beneﬁt from GVHD in preventing
elapse suggests that a GvATLL effect could occur in
atients with ATLL after allo-HSCT without clini-
ally obvious GVHD. [11]
Transplantation-related mortality was a signiﬁ-
ant problem in this study. Five patients (15%) died
ithin 20 days, from infection in 3 patients and TMA
n 2 patients. Nine patients (27%) died within 100
ays, due to infection in 3 patients, TMA in 2 patients,
nd VOD in 1 patient. Patients with ATLL might
ave an increased risk of frequent opportunistic infec-
ion, because they have an associated T-cell immuno-
eﬁciency. Furthermore, ATLL is usually systemic in
Figure 4. Cumulative incidence of disease progressionistribution, and the accumulated organ damages as a tesult of repeated cytotoxic chemotherapy seen in pa-
ients before transplantation may have contributed to
he onset of TMA. In univariate and multivariate
nalysis, recipient age (50 years) and NR disease
tatus at transplantation represented signiﬁcant risk
actors for OS. The multivariate analyses were limited
y the small number of patients in each subgroup;
owever, patients displaying these risk factors tended
o have a higher rate of treatment-related mortality
han patients without these factors, and it can be
ssumed that these risk factors have a signiﬁcant rela-
ionship with outcome clinically. In this study, mostly
yeloablative conditioning regimens were used be-
ore transplantation. Given that conventional allo-
SCT is designed to eradicate tumor cells with my-
loablative intensity using maximally tolerated doses
f high-dose chemotherapy and radiotherapy, the de-
irable effects often may be offset by overwhelming
oxicity in patients age 50 years. Moreover, the
umber of patients with ATLL who are eligible for
llo-HSCT with myeloablative conditioning is lim-
ted, because the typical patient with ATLL has a
elatively advanced age at presentation (about 60
ears). To reduce treatment-related mortality, allo-
SCT with reduced-intensity conditioning offers a
ew treatment option for patients with ATLL who are
neligible for allo-HSCT with myeloablative condi-
ioning due to advanced age or medical inﬁrmity.
30,31] Okamura et al [32] reported on 16 patients age
50 years with ATLL who underwent allo-HSCT
ith reduced-intensity conditioning from HLA-
atched related donors and found that treatment-
elated mortality was acceptable and that allo-HSCT
ith reduced-intensity conditioning was a feasible
d progression-free mortality (---) after transplantation.reatment for ATLL. Given these ﬁndings, UBMT
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red for elderly patients with ATLL.
Another concern related to allo-HSCT for ATLL
nvolves the use of HTLV-1–positive carrier donors.
bout 2/3 of siblings of patients with ATLL are
TLV-I carriers. From the perspective of HTLV-I–
ositive donor risk, granulocyte colony–stimulating
actor (G-CSF) can reportedly stimulate the prolifer-
tion of ATLL cells [33], and HTLV-I–positive do-
ors may be at increased risk of developing ATLL due
o the administration of G-CSF in the setting of allo-
eneic peripheral blood stem cell transplantation.
rom the perspective of patients with ATLL, allo-
SCT from an HTLV-I–positive donor may carry a
isk of HTLV-I–associated disease after allo-HSCT
34] or a risk of promoting the future development of
igure 5. Cumulative incidence of progression-free mortality grou
ransplantation (B).TLL due to the new HTLV-I load on immunocom- aromised recipients [13,14]. On the other hand, to
ate there is no evidence in the JMDP or the literature
hat ATLL can develop from infected HTLV-I–neg-
tive donor cells due to the HTLV-I load of the
ecipient. The HTLV-I proviral load dramatically de-
reased to an undetectable level after transplantation,
specially after transplantation from HTLV-I–nega-
ive donors. [18, 32] This decreased HTLV-I proviral
oad was observed after both myeloablative and re-
uced-intensity conditioning. Transplantation from
n HTLV-I–positive donor is reportedly associated
ith a higher frequency of relapse compared with
ransplantation from an HTLV-I–negative donor.
11] Therefore, the uninfected normal donor T cells
ight overwhelm infected HTLV-I recipient T cells
ue to a GvATLL response and might act as an
cording to pretransplantation factors, age (A) and disease status atped acntiviral therapy. However, an HTLV-I–positive do-
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K. Kato et al.98or might avoid clonal expansion of HTLV-I–in-
ected T lymphocytes after allo-HSCT through the
rovision of cytotoxic T cells. Thus, it is currently
ifﬁcult to determine whether an HTLV-I–positive
r–negative donor should be selected. Longer fol-
ow-up is needed to resolve this issue. In the mean-
ime, a prudent clinical attitude toward both HTLV-
–positive donors and recipients with ATLL is
arranted.
In conclusion, allo-HSCT from an HTLV-I–neg-
tive unrelated donor appears to be an feasible alter-
ative treatment for patients with ATLL for whom an
LA-matched related donor is unavailable. Further
rospective controlled studies are needed to assess the
fﬁcacy of allo-HSCT for ATLL and to deﬁne the
linical indications of allo-HSCT for ATLL, taking
nto account donor selection, the conditioning regi-
en, and the prognostic factors identiﬁed in this
tudy.
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PPENDIX: PARTICIPATING INSTITUTIONS
The following centers in Japan participated in this
tudy: Hokkaido University Hospital, Sapporo Uni-
ersity Hospital, Sapporo Hokuyu Hospital, Japanese
ed Cross Asahikawa Hospital, Asahikawa Medical
ollege Hospital, Hirosaki University Hospital, To-
oku University Hospital, Yamagata University Hos-
ital, Akita University Hospital, Fukushima Medical
ollege, National Cancer Center Central Hospital,
nstitute of Medical Science at the University of To-
yo, Toho University Hospital, Omori Hospital, To-
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ospital, Keio University Hospital, Tokyo Medical
ollege Hospital, Tokyo Medical and Dental Univer-
ity Hospital, Tokyo University Hospital, Yokohama
ity University Hospital, Kanagawa Children’s Med-
cal Center, Kanagawa Cancer Center, Tokai Univer-
ity Hospital, St Marianna University Hospital, Chiba
niversity Hospital, Chiba Children’s Hospital, Mat-
udo Municipal Hospital, Kameda General Hospital,
aitama Children’s Medical Center, Saitama Cancerenter Hospital, Saitama Medical School Hospital,
baraki Children’s Hospital, Jichi Medical School
ospital, Dokkyo University Hospital, Fukaya Red
ross Hospital, Saiseikai Maebashi Hospital, Gunma
niversity Hospital, Niigata University Hospital, Ni-
gata Cancer Center Hospital, Shinshu University
ospital, Saku Central Hospital, Hamamatsu Univer-
ity Hospital, Hamamatsu Medical Center, Shizuoka
eneral Hospital, Shizuoka Children’s Hospital, Jap-
nese Red Cross Nagoya First Hospital, Nagoya
aini Red Cross Hospital, Meitetsu Hospital, Nagoya
niversity Hospital, Nagoya Ekisaikai Hospital, Na-
ional Nagoya Hospital, Aichi Medical School Hospi-
al, Nagoya City University Hospital, Showa Hospi-
al, Anjo Kousei Hospital, Fujita Health University
ospital, Mie University Hospital, Kanazawa Univer-
ity Hospital, Kanazawa Medical University Hospital,
oyama Prefectural Central Hospital, Fukui Medical
chool Hospital, Shiga University of Medical Science,
enter for Adult Disease in Osaka, Kinki University
ospital, Osaka University Hospital, Osaka Medical
enter and Research Institute for Maternal and Child
ealth, Matsushita Memorial Hospital, Hyogo Col-
ege of Medicine Hospital, Hyogo Medical Center for
dults, Kobe City General Hospital, Kobe University
ospital, Kyoto University Hospital, Kyoto Prefec-
ural University of Medicine Hospital, Social Insur-
nce Kyoto Hospital, Tottori Prefectural Central
ospital, Tottori University Hospital, Hiroshima Red
ross Hospital and Atomic-Bomb Survivors Hospital,
amaguchi University Hospital, Ehime Prefectural
entral Hospital, Okayama National Hospital,
urashiki Central Hospital, Kyushu University Hos-
ital, Harasanshin General Hospital, Hamanomachi
eneral Hospital, National Kyushu Cancer Center, St
ary’s Hospital, Kokura Memorial Hospital, Saga
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ospital, Kumamoto University Hospital, Oita Med-
cal University Hospital, Kagoshima University Hos-
ital, and Imamura Bun-in Hospital.
EFERENCES
1. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia:
clinical and hematologic features of 16 cases. Blood. 1977;50:
481-492.
2. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characteriza-
tion of retrovirus from cell lines of human adult T-cell leukemia
and its implication in the disease. Proc Natl Acad Sci USA.
1982;79:2031-2035.
3. Shimoyama M. Diagnostic criteria and classiﬁcation of clinical
subtypes of adult T- cell leukaemia-lymphoma. A report from
the Lymphoma Study Group (1984-87). Br J Haematol. 1991;
79:428-437.
4. Kuwazuru Y, Hanada S, Furukawa T, et al. Expression of
P-glycoprotein in adult T-cell leukemia cells. Blood. 1990;76:
2065-2071.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
Unrelated Bone Marrow Transplantation for Adult T-Cell Leukemia/Lymphoma 995. Ikeda K, Oka M, Yamada Y, et al. Adult T-cell leukemia cells
over-express the multidrug-resistance-protein (MRP) and lung-
resistance-protein (LRP) genes. Int J Cancer. 1999;82:599-604.
6. Taguchi H, Kinoshita KI, Takatsuki K, et al. An intensive
chemotherapy of adult T-cell leukemia/lymphoma: CHOP fol-
lowed by etoposide, vindesine, ranimustine, and mitoxantrone
with granulocyte colony-stimulating factor support. J Acquir
Immune Deﬁc Syndr Hum Retrovirol. 1996;12:182-186.
7. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF–
supported combination chemotherapy, LSG15, for adult T-cell
leukaemia-lymphoma: Japan Clinical Oncology Group Study
9303. Br J Haematol. 2001;113:375-382.
8. Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of
autologous stem cell transplantation for adult T cell leukemia/
lymphoma: a case report and review of the literature. Bone
Marrow Transplant. 1999;23:87-89.
9. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved out-
come of adult T-cell leukemia/lymphoma with allogeneic he-
matopoietic stem cell transplantation. Bone Marrow Transplant.
2001;27:15-20.
0. Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haemato-
poietic stem cell transplantation for the treatment of adult
T-cell leukaemia/lymphoma. Br J Haematol. 2003;120:304-309.
1. Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hemato-
poietic stem cell transplantation provides sustained long-term
survival for patients with adult T-cell leukemia/lymphoma.
Leukemia. 2005;19:829-834.
2. Momita S, Ikeda S, Amagasaki T, et al. Survey of anti-human
T-cell leukemia virus type I antibody in family members of
patients with adult T-cell leukemia. Jpn J Cancer Res. 1990;81:
884-889.
3. Chen YC, Wang CH, Su IJ, et al. Infection of human T-cell
leukemia virus type I and development of human T-cell leuke-
mia lymphoma in patients with hematologic neoplasms: a pos-
sible linkage to blood transfusion. Blood. 1989;74:388-394.
4. Tamaki H, Matsuoka M. Donor-derived T-cell leukemia after
bone marrow transplantation. N Engl J Med. 2006;354:1758-
1759.
5. Ogata M, Ogata Y, Imamura T, et al. Successful bone marrow
transplantation from an unrelated donor in a patient with adult
T cell leukemia. Bone Marrow Transplant. 2002;30:699-701.
6. Ishikawa T. Current status of therapeutic approaches to adult
T-cell leukemia. Int J Hematol. 2003;78:304-311.
7. Izutsu K, Kanda Y, Ohno H, et al. Unrelated bone marrow
transplantation for non-Hodgkin lymphoma: a study from the
Japan Marrow Donor Program. Blood. 2004;103:1955-1960.
8. Nakase K, Hara M, Kozuka T, et al. Bone marrow transplan-
tation from unrelated donors for patients with adult T-cell
leukaemia/lymphoma. Bone Marrow Transplant. 2006;37:41-44.
9. Terasaki PI, McClelland JD. Microdroplet assay of human
serum cytotoxins. Nature. 1964;204:998-1000.
0. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of
class I HLA alleles on clinical outcome after transplantation ofhematopoietic stem cells from an unrelated donor. N Engl
J Med. 1998;339:1177-1185.
1. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestation of
graft-versus-host disease in human recipients of marrow from
HLA-matched sibling donors. Transplantation. 1974;18:295-304.
2. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 trans-
plantations from unrelated donors facilitated by the National
Marrow Donor Program. N Engl J Med. 1993;328:593-602.
3. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic cuta-
neous graft-versus-host syndrome on man: a long-term clini-
copathologic study of 20 Seattle patients. Am J Med. 1980;69:
204-217.
4. Gooley TA, Leisenring W, Crowley J, et al. Estimation of
failure probabilities in the presence of competing risks: new
representations of old estimators. Stat Med. 1999;18:695-706.
5. Oken MM, Creech RH, Tormey DC, et al. Toxicity and
response criteria of the Eastern Cooperative Oncology Group.
Am J Clin Oncol. 1982;5:649-655.
6. Bierman PJ, Molina L, Nelson G, et al. Matched unrelated
donor (MUD) allogeneic bone marrow transplantation for
Non-Hodgkin’s lymphoma (NHL): results from the National
Marrow Donor Program (NMDP) [abstract]. Proc Am Soc Clin
Oncol. 1999;18:3a.
7. Morishima Y, Kodera Y, Hirabayashi N, et al. Low incidence of
acute GVHD in patients transplanted with marrow from
HLA-A, B, DR-compatible unrelated donors among Japanese.
Bone Marrow Transplant. 1995;15:235-239.
8. Kodera Y, Morishima Y, Kato S, et al. Analysis of 500 bone
marrow transplants from unrelated donors (UR-BMT) facili-
tated by the Japan Marrow Donor Program: conﬁrmation of
UR-BMT as a standard therapy for patients with leukemia and
aplastic anemia. Bone Marrow Transplant. 1999;24:995-1003.
9. Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-
tax response in adult T-cell leukemia patients after hematopoi-
etic stem cell transplantation. Cancer Res. 2004;64:391-399.
0. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic
hematopoietic progenitor ccells with purine analog-containing
chemotherapy: harnessing graft-versus-leukemia without my-
eloablative therapy. Blood. 1997;89:4531-4536.
1. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem
cell transplantation and cell therapy as an alternative to con-
ventional bone marrow transplantation with lethal cytoreduc-
tion for the treatment of malignant and nonmalignant hema-
tologic diseases. Blood. 1998;91:756-763.
2. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-
cell transplantation with reduced conditioning intensity as a
novel immunotherapy and antiviral therapy for adult T-cell
leukemia/lymphoma. Blood. 2005;105:4143-4245.
3. Matsushita K, Arima N, Ohtsubo H, et al. Granulocyte-colony
stimulating factor-induced proliferation of primary adult T-cell
leukaemia cells. Br J Haematol. 1997;96:715-723.
4. Imirizaldu JJ, Esteban JC, Axpe IR, et al. Post-transplantation
HTLV-1 myelopathy in three recipients from a single donor.
J Neurol Neurosurg Psychiatry. 2003;74:1080-1084.
